Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

US: Federal Trade Commission issues report on reverse settlement agreements in FY2010 (Patent Docs) (Orange Book Blog) (FDA Law Blog)

US: Billups-Rothenberg v. ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

UNCTAD: Bundle of opportunities to improve medicines access in LDCs (IP Watch)

Australia: Why IP professionals must take ‘gene patent’ opponents seriously (Patentology)

Australia: FCA finds fatal flaw in Plant Breeders Rights Act: Elders Rural Services Australia Limited v Registrar of Plant Breeder’s Rights (Patentology) (ipwars)

Finland: Decision on parallel import of pharmaceuticals (Class 46)

Italy: Again on MA filing as a preparatory act of marketing – The Court of Turin on Art. 68 (1bis) IP Code (Kluwer Patent Blog)

Lithuania: Supreme Court of Lithuania concludes SPC application period lapsed in Kirin Amgen, Inc. v. State Patent Bureau of the Republic of Lithuania (Kluwer Patent Blog)

Spain: Modification of EP translations (2) – Supreme Court grants fourth appeal, filed again by Pfizer: EP0325571 (PatLit)

US: Federal Trade Commission issues report on reverse settlement agreements in FY2010 (Patent Docs) (Orange Book Blog) (FDA Law Blog)

US: FTC posts friendly reminder to please send them your ANDA litigation settlement agreements (Orange Book Blog)

US: Billups-Rothenberg v. ARUP: Genetic testing patents found to be anticipated and in violation of Lilly written description requirement (Holman’s Biotech IP Blog) (Patent Docs) (Patently-O)

US: FDA gets the ball rolling on biosimilar/interchangeable biological product user fee program; proposal gives a hat tip to PDUFA while acknowledging the nascent state of the industry (FDA Law Blog) (Patent Docs)

Products

Citalopram – UK Patents Court disapproving of EPO’s approach to assessment of novelty: Lundbeck v Norpharma, Infosint & Ors (Kluwer Patent Blog) (EPLAW)

Colcrys (Colchicine) – US: Mutual Pharmaceutical files patent infringement complaint against West-Ward Pharmaceuticals following NDA filing (Patent Docs) (IPBiz)

Cymbalta (Duloxetine) – US: Eli Lilly successfully blocks release of generic Cymbalta: Eli Lilly v Wockhardt et al (Patent Docs)

Escitalopram – Spain: Injunction lifted as Spanish Escitalopram dispute edges towards full trial (The SPC Blog)

Evopad – Spain: Spanish court orders the Administration to bear the damages caused by the erroneous price reduction (Kluwer Patent Blog)

Intuniv (Guanfacine) – US: Shire files patent infringement complaint against Mylan based on ANDA filing (Patent Docs)

Myfortic (Mycophenolate) – US: Novartis files patent infringement complaint against Teva in response to Para IV challenge (Patent Docs)

Neurontin (Gabapentin) – US: Pfizer and Eon settle Neurontin patent dispute (Patent Docs)

Restasis (Ciclosporin) – US: N D Illinois: Another court upholds constitutionality of false marking statute: Simonian v. Allergan, Inc. (Docket Report)

Risedronate – Israel: Patent for hydrated salt of Risedronate refused in Israel opposition (IP Factor)

Seroquel (Quetiapine) – US: Seroquel suit between AstraZeneca and Biovail dismissed (Patent Docs)

Valcyte (Valganciclovir) – US: Genentech files patent infringement suit against Sandoz in response to Para IV certification filing (Patent Docs)

Viagra (Sildenafil) – Canada Supreme Court to hear challenge to Pfizer’s Viagra patent by Teva Canada (The IP Factor)

Yaz (Drospirenone, Ethinyl estradiol) – US: Bayer Schering files patent infringement complaints against Mylan in Nevada, West Virginia and New Jersey in response to Para IV certification (Patent Docs)